Adia Med of Winter Park LLC Lower Back Pain Research Study

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-85
SponsorAdia Med of Winter Park LLC

About this trial

The goal of this clinical study is to evaluate the safety and preliminary efficacy of an investigational umbilical cord blood-derived stem cell and exosome infusion in adults with chronic lower back pain associated with degenerative spine disease. The primary questions this study aims to answer are whether the investigational infusion is safe and well tolerated and whether treatment may reduce pain and improve physical function and quality of life. Researchers will compare the investigational infusion to a placebo (saline solution) to evaluate potential treatment effects in participants with chronic mechanical lower back pain. Participants will receive either the investigational infusion or placebo intravenously during a study visit, complete pain, disability, and quality-of-life assessments, undergo magnetic resonance imaging (MRI) and laboratory testing, and attend follow-up evaluations over a 6-month period. Participants initially assigned to placebo may later receive the investigational treatment during an open-label crossover phase of the study.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18-85 years

Chronic lower back pain ≥3 months

Baseline VAS-Average ≥4/10

Able to comply with study visits and procedures

Disqualifiers

Pregnancy or breastfeeding

Prisoners or decisionally impaired adults

Active malignancy (except non-melanoma skin cancer)

Immunodeficiency or active systemic infection

Trial design

Design model

Crossover

Treatments tested in this trial

  • Umbilical Cord Blood-Derived Stem Cells and Exosomes

    Biological/Vaccine

    Intravenous infusion of cryopreserved allogeneic umbilical cord blood-derived product containing viable mononuclear cells (including hematopoietic and mesenchymal stem/stromal cells) and exosomes.

  • Placebo IV

    Other intervention

    Matched placebo intravenous infusion (administered in the same volume and manner as stem cell and exosome product).

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: Stem CellExperimental treatment 1 intervention
Group B: Placebo Control (with Crossover)Placebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in Average Low Back Pain Intensity From Baseline to Month 3

Measured using the Visual Analog Scale (VAS-Average), a 0-10 scale assessing average low back pain intensity over the past week, with higher scores indicating greater pain severity.

Time frame
Baseline to Month 3
2

Change in Functional Disability From Baseline to Month 3

Measured using the Oswestry Disability Index (ODI), a validated questionnaire assessing disability related to low back pain, scored from 0-100%, with higher scores indicating greater disability.

Time frame
Baseline to Month 3

Secondary outcomes

1

Incidence of Treatment-Emergent Adverse Events (TEAEs)

Assessment of safety and tolerability based on the frequency, severity, and relationship of adverse events following investigational infusion, graded using Common Terminology Criteria for Adverse Events (CTCAE v5.0).

Time frame
Baseline through Month 6

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.